IMMUPHARMA (LON:IMM)
SECTOR – HEALTHCARE
RATING – BUY*
MARKET CAP – £75m
CURRENT PRICE – 56p
TARGET PRICE – 171p
COMPANY DESCRIPTION
ImmuPharma PLC is a late clinical stage drug development business specialising in the area of autoimmune disease.
Lupuzor trial update
NORTHLAND VIEW
ImmuPharma issued an update on its pivotal 52-week, randomised, double-blinded, Phase 3 clinical trial of Lupuzor™, its lead programme for the potential treatment of Lupus. Key highlights included:
All 200 patients have passed the 3 months stage
Over 80% of patients (166) have passed the 6 months stage
49 patients have passed the 9 months stage
28 patients have passed the full 12 months of the study
The study to date supports Lupuzor™'s robust safety profile
Top line results remain on track to be reported in Q1 2018
Lupuzor continues to progress well through its pivotal Phase 3 trial. All 200 patients have now passed the three months stage. Importantly, 80% of patients have had exposure to Lupuzor™ for over six months and the drug continues to maintain an excellent safety profile. Finally, the study is on track to report top line results in Q1 2018. We continue to believe that ImmuPharma is grossly undervalued: should Lupuzor be approved, we estimate it could achieve multi-billion dollar annual sales.